Polyclonal Antibody to Androgen Receptor (AR)
| Code | Size | Price |
|---|
| PAB252Ra02-20ul | 20ul | £89.00 |
Quantity:
| PAB252Ra02-100ul | 100ul | £166.00 |
Quantity:
| PAB252Ra02-200ul | 200ul | £224.00 |
Quantity:
| PAB252Ra02-1ml | 1ml | £515.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
AIS; DHTR; HUMARA; KD; NR3C4; SBMA; SMAX1; TFM; Dihydrotestosterone receptor; Nuclear Receptor Subfamily 3,Group C,Member 4; Testicular Feminization; Kennedy Disease
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Androgen Receptor
Reactivity:
Hu;Mu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:500-2000
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Androgen Receptor (AR) | RPB252Ra02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||